FDA warned The Truth Company, Kinobody and UMZU that website claims made nine supplements unapproved new drugs and misbranded (improperly labeled).
What happened
In June 2022, FDA reviewed www.umzu.com and www.kinobody.com and found they take orders for Betaine, Immune, Redwood, Sensolin, Thyrite, zuRelief, Kino Aminos, Kino Collagen Protein, and Kino Gains. FDA cited website claims that the products treat or prevent diseases such as diabetes, colds, high blood pressure, and arthritis. FDA said this makes them unapproved new drugs—products that need FDA approval before sale—and that six of them also lack adequate directions for use and are misbranded (improperly labeled).
What FDA found
FDA says website claims that the products cure, mitigate, treat, or prevent disease make them drugs under the law.
section 201(g)(1)(B) of the Act [21 U.S.C. § 321(g)(1)(B)]FDA says the products are not generally recognized as safe and effective for those uses, so they are 'new drugs.'
section 201(p) of the Act [21 U.S.C. § 321(p)]FDA says the products are unapproved new drugs and cannot be introduced into interstate commerce without prior approval.
sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]FDA says Betaine, Immune, Redwood, Sensolin, Kino Aminos, and Kino Gains fail to bear adequate directions for their intended use and are misbranded.
section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]FDA says those six products are intended for diseases that a layperson cannot safely diagnose or treat without a licensed practitioner, so adequate directions cannot be written.
section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]FDA says introducing or delivering these misbranded drugs into interstate commerce violates the Act.
section 301(a) of the Act [21 U.S.C. § 331(a)]
What FDA wants
Within 15 working days of receipt, FDA asks the company to notify it in writing of specific corrective steps, explanations, and related documentation. If corrections cannot be completed in that time, the company must explain the delay and give a completion date; if it believes there is no violation, it must provide reasoning and supporting information.
Who should pay attention
- dietary supplement brands that make disease-related claims
- e-commerce sellers of supplements with wellness claims
- companies using blog content to market supplements
This is a summary. Read the original letter on fda.gov.